Avaliação imuno-histoquímica de 100 casos de metástases encefálicas e correlação com o sítio primário do tumor

Cambruzzi, Eduardo; Pêgas, Karla Laís; Ferrari, Márcio B.

doi:10.1590/s1676-24442011000100008

Cited by 1 publication

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the northern region of Brazil, it is the second most frequent cancer (19/100,000 women) after cervical cancer (INCA, 2012). An immunohistochemical study of 100 Brazilian patients (Porto Alegre, RS) suggested breast cancer as the primary origin of brain metastasis in 16% of the studied cases (Cambruzzi et al, 2011); these results confirm data ascertained in other countries, although the overall incidence may be as high as 30% according to molecular studies (Marko et al, 2012). The outcome for patients with brain metastasis derived from breast tumors is poor, and the overall survival after diagnosis varies between 2-16 months, with only 20% of patients reaching the 12-month mark (Cheng and Hung, 2007).…”

Section: Introductionsupporting

confidence: 78%

“…It has been demonstrated that primary breast cancer with a basal-like immunophenotype has the propensity to metastasize to the brain (Espinosa et al, 2006). Indeed, breast cancer is the second most common source of brain metastases after lung cancer, representing 14-20% of all cases (Fulford et al, 2007;Cambruzzi et al, 2011). Although the incidence of breast metastasis in the brain is high, and metastatic transition involves the occurrence of many chromosomal abnormalities (Lohr et al, 2001), little is known about the behavior of chromosomes in metastases.…”

Section: Discussionmentioning

confidence: 99%

“…Of the approximately 1.3 million people diagnosed with cancer in the United States each year, approximately 100,000 to 170,000 will develop brain metastases; this corresponds to an annual incidence of around 4.1 to 11.1 per 100,000 individuals (Barnholtz-Sloan et al, 2004;Cambruzzi et al, 2011). Large autopsy studies suggest that approximately 20 to 40% of all patients with metastatic cancer have brain metastases (http://www.cancer.org; Weil et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

“…The most common primary metastatic sites in adults are the lung (35%), central nervous system (CNS; 25-30%) and breast (14-18%; Weil et al, 2005;Cambruzzi et al, 2011;Saunus et al, 2011). This phenomenon is called organotropism, which means that the distribution of metastasis in different organs is nonrandom; i.e., the tumor cells could have specific affinity for the microenvironments of certain organs (Talmadge and Fidler, 2010;Saunus et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Numerical aberrations of chromosome 17 and TP53 in brain metastases derived from breast cancer

Vasconcelos¹,

Silva²,

Quintana³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Breast cancer is the second most common origin of brain metastases, after lung cancer, and represents 14-20% of all cases. Abnormalities of chromosome 17 are important molecular genetic events in human breast cancer, and several oncogenes and tumor suppressor genes are located on this chromosome. In about half of all human cancers, the tumor suppressor gene TP53, located at 17p13, is either lost or mutated. Loss of p53 protein function influences not only cell cycle checkpoint controls and apoptosis, but also the regulation of other important stages of metastatic progression, such as cell migration and tissue invasion. The aim of our study was to identify numerical aberrations of chromosome 17 and TP53 in 5 subjects with brain metastasis from breast cancer using dual-color fluorescence in situ hybridization experiments. Deletion of TP53 was the most frequent alteration observed, suggesting that if this alteration is present in the primary tumors, breast tumors with loss of TP53 copies have a poorer prognosis and a higher chance for metastasis. If this is true, the analyses of chromosome 17 and TP53 in primary breast cancer could be important for predicting its metastatic potential.

show abstract

Section: Introductionsupporting

confidence: 78%